Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

cancer
bone marrow procedure
monoclonal antibody therapy
lymphoma
b-cell lymphoma
  • 4 views
  • 07 Oct, 2022
  • 12 locations
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab in Japanese patients with relapsed, progressive or refractory B-cell lymphomas and Japanese patients with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior SOC. The trial consists of two parts: Part 1, …

chop regimen
prednisone
lymphoma
follicular lymphoma
monoclonal protein
  • 0 views
  • 07 Oct, 2022
  • 11 locations
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

hodgkin's disease
ejection fraction
tyrosine
lymphoma
b-cell lymphoma
  • 280 views
  • 27 Jan, 2022
  • 23 locations
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human dose escalation and cohort expansion multicenter, open-label study designed to evaluate the safety and preliminary efficacy of NX-5948 in patients with advanced B-cell malignancies.

  • 1 views
  • 07 Oct, 2022
  • 4 locations
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

cancer chemotherapy
lymphoma
tyrosine
gilbert's syndrome
follicular lymphoma
  • 0 views
  • 13 May, 2022
  • 1 location
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia

monoclonal antibodies
lymphoma
b-cell lymphoma
chronic lymphocytic leukemia
monoclonal protein
  • 0 views
  • 17 Oct, 2022
  • 5 locations
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety …

chemotherapy regimen
cancer
cell transplantation
bendamustine
cancer chemotherapy
  • 5 views
  • 04 Oct, 2022
  • 8 locations
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the …

obinutuzumab
cancer
lymphoid leukemia
lymphoma
gilbert's syndrome
  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

hodgkin's disease
anticancer agents
lymphoma
refractory lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 18 Oct, 2022
  • 2 locations
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or …

refractory follicular lymphoma
lung carcinoma
lymphoma
solid tumor
chronic lymphocytic leukemia
  • 24 views
  • 04 Oct, 2022
  • 11 locations